International Cancer Conference Journal

, Volume 8, Issue 1, pp 24–28 | Cite as

A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib

  • Hironori KitadeEmail author
  • Koushiro Ohtsubo
  • Kengo Hokkoku
  • Mitsue Mori
  • Robert Yoshiyuki Osamura
  • Hiroshi Sakuma
  • Masuo Nakai
  • Seiji Yano
Case report


Molecular targeted drugs, such as everolimus and sunitinib, have shown efficacy against advanced pancreatic neuroendocrine tumors. Octreotide, a somatostatin analogue, improves the hormone-related symptoms in patients with neuroendocrine tumors. Furthermore, it has been reported that octreotide has antitumor activity in patients with metastatic midgut neuroendocrine tumors. However, whether octreotide has anti-proliferative effects in patients with advanced pancreatic neuroendocrine tumors is not fully understood. We report a 71-year-old man with multiple liver metastases of pancreatic neuroendocrine tumor. He was treated with everolimus 10 mg daily and sunitinib 25 mg daily on days 1–14 every 3 weeks at the physician’s discretion. However, these molecular targeted drugs were discontinued due to disease progression or severe adverse effects. Octreotide long-acting repeatable was administered continuously from the initiation of everolimus treatment. The tumor marker level markedly decreased and the metastatic liver lesions showed shrinkage with octreotide treatment. Immunohistochemistry of tumor specimens obtained before treatment showed that somatostatin receptor 2, a high-affinity receptor for octreotide, was highly expressed. The clinical course of this patient suggested that octreotide long-acting repeatable may be a treatment option for advanced pancreatic neuroendocrine tumors after failure of everolimus and sunitinib. Further clinical trials are warranted to determine whether the expression of somatostatin receptor 2 in tumor tissues is predictive of octreotide efficacy.


Pancreatic neuroendocrine tumor Octreotide Somatostatin receptor 



We thank all staff members of Houju Memorial Hospital that provided the patient’s data in this case report.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Human rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Written informed consent was obtained from the patient‘s next of kin for the publication of this case report and any accompanying images.


  1. 1.
    Halfdanarson TR, Rabe KG, Rubin J et al (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733CrossRefGoogle Scholar
  2. 2.
    Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRefGoogle Scholar
  3. 3.
    Ballian N, Loeffler AG, Rajamanickam V et al (2009) A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford) 11:422–428CrossRefGoogle Scholar
  4. 4.
    Caplin ME, Pavel M, Ćwikła JB et al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224–233CrossRefGoogle Scholar
  5. 5.
    Wolin EM, Jarzab B, Eriksson B et al (2015) Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 9:5075–5086CrossRefGoogle Scholar
  6. 6.
    Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523CrossRefGoogle Scholar
  7. 7.
    Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513CrossRefGoogle Scholar
  8. 8.
    Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663CrossRefGoogle Scholar
  9. 9.
    Bosman FT, Carneiro F, Hruban RH et al (2010) WHO classification of tumours of the digestive system. IARC Press, Lyon, France, pp 13–14Google Scholar
  10. 10.
    di Bartolomeo M, Bajetta E, Buzzoni R et al (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77:402–408CrossRefGoogle Scholar
  11. 11.
    Møller LN, Stidsen CE, Hartmann B (2003) Somatostatin receptors. Biochim Biophys Acta 1616:1–84CrossRefGoogle Scholar
  12. 12.
    Susini C, Buscail L (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733–1742CrossRefGoogle Scholar
  13. 13.
    Ferrante E, Pellegrini C, Bondioni S et al (2006) Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 13:955–962CrossRefGoogle Scholar
  14. 14.
    Lamberts SWJ, Van der Lely AJ, de Herder WW et al (1996) Octreotide. N Engl J Med 334:246–254CrossRefGoogle Scholar
  15. 15.
    Lee L, Ito T, Igarashi H et al (2018) Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 81:163–169CrossRefGoogle Scholar
  16. 16.
    Ricci S, Antonuzzo A, Galli L et al (2000) Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 11:1127–1130CrossRefGoogle Scholar
  17. 17.
    Gonzalez B, Vargas G, Ramirez C et al (2014) Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide. Endocrinol Nutr 61:523–530CrossRefGoogle Scholar
  18. 18.
    Brunner P, Jörg AC, Glatz K et al (2017) The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 44:468–475CrossRefGoogle Scholar
  19. 19.
    Butturini G, Bettini R, Missiaglia E et al (2006) Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 13:1213–1221CrossRefGoogle Scholar
  20. 20.
    Panzuto F, Di Fonzo M, Iannicelli E et al (2006) Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 17:461–466CrossRefGoogle Scholar
  21. 21.
    Imhof A, Brunner P, Marincek N et al (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29:2416–2423CrossRefGoogle Scholar
  22. 22.
    Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130CrossRefGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2018

Authors and Affiliations

  • Hironori Kitade
    • 1
    Email author
  • Koushiro Ohtsubo
    • 4
  • Kengo Hokkoku
    • 1
  • Mitsue Mori
    • 1
  • Robert Yoshiyuki Osamura
    • 5
  • Hiroshi Sakuma
    • 2
  • Masuo Nakai
    • 2
  • Seiji Yano
    • 3
    • 4
  1. 1.Department of PharmacyHouju Memorial HospitalNomiJapan
  2. 2.Department of SurgeryHouju Memorial HospitalNomiJapan
  3. 3.Outpatient Cancer Chemotherapy CenterHouju Memorial HospitalNomiJapan
  4. 4.Division of Medical Oncology, Cancer Research InstituteKanazawa UniversityKanazawaJapan
  5. 5.Department of PathologyInternational University of Health and Welfare Mita HospitalTokyoJapan

Personalised recommendations